Published in Hepatology on October 01, 2001
A Prospective Cohort Study to Improve HCV Care in Dialysis Patients (MATCH-D) | NCT03791814
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis (2010) 2.96
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Prevention and treatment of hepatitis C in injection drug users. Hepatology (2002) 1.88
Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol (2012) 1.85
Hepatitis C virus genotype frequency in Isfahan province of Iran: a descriptive cross-sectional study. Virol J (2010) 1.75
The history of the "natural history" of hepatitis C (1968-2009). Liver Int (2009) 1.63
Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. J Viral Hepat (2015) 1.40
The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One (2014) 1.25
Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut (2005) 1.24
Patients' preferences for treatment of hepatitis C. Med Decis Making (2009) 1.20
Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 1.19
Best strategies for global HCV eradication. Liver Int (2013) 1.16
Quantification of hepatitis C virus in human liver and serum samples by using LightCycler reverse transcriptase PCR. J Clin Microbiol (2002) 1.14
Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening. Am J Public Health (2010) 1.12
Occult persistence and lymphotropism of hepatitis C virus infection. World J Gastroenterol (2008) 1.01
Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health (2013) 1.01
Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infect Dis (2007) 1.00
Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings. Am J Public Health (2014) 0.99
Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol (2013) 0.98
Molecular mechanisms of insulin resistance in chronic hepatitis C. World J Gastroenterol (2009) 0.98
Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J Virol (2009) 0.92
Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet (2014) 0.92
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction (2015) 0.92
Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol (2008) 0.92
HIV and co-infections. Immunol Rev (2013) 0.92
Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Ther Adv Chronic Dis (2011) 0.91
Liver transplantation for alcoholic liver disease. World J Gastroenterol (2010) 0.91
Hepatitis C and general practice: the crucial role of primary care in stemming the epidemic. Br J Gen Pract (2005) 0.90
Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World J Hepatol (2015) 0.88
Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. PLoS One (2011) 0.88
Therapeutic challenges in hepatitis C-infected injection drug using patients. Harm Reduct J (2006) 0.88
Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci (2013) 0.88
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS (2014) 0.87
Elevated alanine aminotransferase is strongly associated with incident metabolic syndrome: a meta-analysis of prospective studies. PLoS One (2013) 0.86
Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats. Virol J (2009) 0.86
Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence (2012) 0.86
Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline. J Infect Dis (2012) 0.86
Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients. Hepat Mon (2011) 0.85
A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland. Br J Cancer (2008) 0.84
Historical trends and projected hospital admissions for chronic hepatitis C infection in Canada: a birth cohort analysis. CMAJ Open (2014) 0.84
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. Glob Public Health (2014) 0.84
Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol (2015) 0.83
IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol (2013) 0.82
Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol (2014) 0.82
Long-term effects of antiviral therapy in patients with chronic hepatitis C. Hepat Res Treat (2010) 0.81
Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol (2014) 0.81
Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation. World J Gastroenterol (2011) 0.80
Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol (2016) 0.80
Plasma proteome analysis reveals overlapping, yet distinct mechanisms of immune activation in chronic HCV and HIV infections. J Acquir Immune Defic Syndr (2013) 0.79
Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2. Virol J (2011) 0.79
Preserved MHC-II antigen processing and presentation function in chronic HCV infection. Cell Immunol (2010) 0.79
Perinatal hepatitis C virus infection: diagnosis and management. Arch Dis Child (2006) 0.79
How do persistent infections with hepatitis C virus cause liver cancer? Curr Opin Virol (2015) 0.79
Transient elastography and APRI score: looking at false positives and false negatives. Diagnostic performance and association to fibrosis staging in chronic hepatitis C. Braz J Med Biol Res (2016) 0.79
Adiponectin serum level in chronic hepatitis C infection and therapeutic profile. World J Hepatol (2015) 0.78
Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C. Dig Dis Sci (2015) 0.78
Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome. PLoS One (2013) 0.78
Efficient virus assembly, but not infectivity, determines the magnitude of hepatitis C virus-induced interferon alpha responses of plasmacytoid dendritic cells. J Virol (2014) 0.77
A Persistent Dementia-like Condition Following Treatment of Hepatitis C With Pegylated Interferon and Ribavirin. Gastroenterol Hepatol (N Y) (2008) 0.77
Hepatitis C virus replication and potential targets for direct-acting agents. Therap Adv Gastroenterol (2010) 0.77
Health state utilities associated with attributes of treatments for hepatitis C. Eur J Health Econ (2014) 0.77
Occult hepatitis C virus infection and its relevance in clinical practice. J Clin Exp Hepatol (2012) 0.77
Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. Can J Gastroenterol (2006) 0.77
"Seek, test, treat and retain" for hepatitis C in the United States criminal justice system. Int J Prison Health (2014) 0.77
Predictors of liver-related death among people who inject drugs in Vancouver, Canada: a 15-year prospective cohort study. J Int AIDS Soc (2014) 0.77
The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China. PLoS One (2015) 0.76
Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. J Clin Transl Hepatol (2016) 0.76
Hepatitis C Virus Disease Progression in People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis. JMIR Res Protoc (2015) 0.76
Outcome of combination antiviral therapy in chronic hepatitis C virus infection during therapy of acute lymphoblastic leukemia. Saudi J Gastroenterol (2011) 0.76
Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. Clin Interv Aging (2016) 0.75
Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. Balkan Med J (2016) 0.75
Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort. Am J Hematol (2016) 0.75
Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients. Drugs R D (2015) 0.75
Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. Int J Med Sci (2017) 0.75
Routine Laboratory Blood Tests May Diagnose Significant Fibrosis in Liver Transplant Recipients with Chronic Hepatitis C: A 10 Year Experience. J Clin Transl Hepatol (2016) 0.75
Epidemiological Survey of Hepatitis C Virus Infection in Fife, Scotland. Gastroenterology Res (2009) 0.75
Effect of HLA on hepatitis C virus clearance and persistence in anti-HCV-positive end-stage renal disease patients. Saudi J Gastroenterol (2014) 0.75
Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. Infect Dis (Lond) (2015) 0.75
An effectiveness study of group psychoeducation for hepatitis C patients in community clinics. Eur J Gastroenterol Hepatol (2017) 0.75
Is exposure to Agent Orange a risk factor for hepatocellular cancer?-A single-center retrospective study in the U.S. veteran population. J Gastrointest Oncol (2016) 0.75
Hepatitis C Virus Infection of Cultured Human Hepatoma Cells Causes Apoptosis and Pyroptosis in Both Infected and Bystander Cells. Sci Rep (2016) 0.75
Pegylated interferon alfa and ribavirin for children with chronic hepatitis C. World J Gastroenterol (2013) 0.75
Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. PLoS One (2017) 0.75
Influence of higher BMI for hepatitis B- and C-related hepatocellular carcinomas. Langenbecks Arch Surg (2017) 0.75
The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin (2017) 0.75
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat (2006) 5.10
Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med (1993) 4.94
Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science (1993) 4.75
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (1999) 3.28
Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet (1997) 2.97
Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis (2009) 2.68
Adjuvant psychological therapy for patients with cancer: a prospective randomised trial. BMJ (1992) 2.68
Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ (1998) 2.64
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Clinical spectrum of HIV/AIDS in the Asia-Pacific region. AIDS (1998) 2.19
Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat (2009) 2.18
Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med (1994) 2.18
What is myalgic encephalomyelitis? Lancet (1988) 2.17
HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust (1998) 2.16
Surgical practice is evidence based. Br J Surg (1997) 2.06
A controversial consensus--comment on article by Broderick et al. J Intern Med (2011) 2.06
Chemokines: leucocyte recruitment and activation cytokines. Lancet (1997) 2.05
Trends in infectious disease mortality in Australia, 1979-1994. Med J Aust (1998) 2.02
Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ (1997) 1.92
Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs. Med J Aust (2000) 1.92
Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis (1997) 1.90
Transmission of hepatitis C within Australian prisons. Med J Aust (1999) 1.89
The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust (1999) 1.85
Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A (1994) 1.84
The role of initial AIDS-defining illness in survival following AIDS. AIDS (1995) 1.82
Acquired immunodeficiency without evidence of HIV infection: national retrospective survey. BMJ (1994) 1.78
Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet (1999) 1.74
Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. Br J Cancer (1988) 1.74
Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS (2001) 1.72
How many dependent heroin users are there in Australia? Med J Aust (2000) 1.71
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest (1997) 1.62
Incidence and risk factors for urethral and anal gonorrhoea and chlamydia in a cohort of HIV-negative homosexual men: the Health in Men Study. Sex Transm Infect (2006) 1.59
Fatigue in selected primary care settings: sociodemographic and psychiatric correlates. Med J Aust (1996) 1.55
Perinatal exposure to HIV in Australia, 1982-1994. Med J Aust (1997) 1.54
Dichotomous effects of beta-chemokines on HIV replication in monocytes and monocyte-derived macrophages. J Immunol (1998) 1.54
Survival analyses of randomized clinical trials adjusted for patients who switch treatments. Stat Med (1996) 1.54
HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med (2003) 1.52
Sexual risk behavior and risk factors for HIV-1 seroconversion in homosexual men participating in the Tricontinental Seroconverter Study, 1982-1994. Am J Epidemiol (1997) 1.52
Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust (2000) 1.50
Safety of myocardial flash-contrast echocardiography in combination with dobutamine stress testing for the detection of ischaemia in 5250 studies. Heart (2008) 1.49
Risk of cancer in people with AIDS. AIDS (1999) 1.47
Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room. AIDS (1996) 1.46
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy. Ir Med J (2013) 1.46
Oral contraceptives and breast cancer: a national study. Br Med J (Clin Res Ed) (1986) 1.44
Association between HIV distal symmetric polyneuropathy and Mycobacterium avium complex infection. J Neurol Neurosurg Psychiatry (1996) 1.44
Detection of HCV RNA in semen. Lancet (2000) 1.41
Chronic fatigue syndrome: current perspectives on evaluation and management. Med J Aust (1995) 1.41
Premature mortality in Australia 1983-1992, the first decade of the AIDS epidemic. Med J Aust (1995) 1.40
Foster care: an update. J Am Acad Child Adolesc Psychiatry (1997) 1.40
Sexually transmissible diseases surveillance in Australia: towards a coordinated national system. Commun Dis Intell (1998) 1.40
Use of interventions for reducing mother-to-child transmission of HIV in Australia. Med J Aust (2001) 1.40
HIV and hepatitis C coinfection within the CAESAR study. HIV Med (2004) 1.39
Allelotype of human bladder cancer. Cancer Res (1994) 1.38
Reporting of occupational exposures to blood-borne pathogens in Australian teaching hospitals. Med J Aust (1995) 1.38
Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer (1987) 1.37
Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med (2007) 1.36
Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis (2011) 1.32
A national surveillance system for newly acquired HIV infection in Australia. National HIV Surveillance Committee. Am J Public Health (1994) 1.32
Circumcision and male-to-male sexual transmission of HIV. AIDS (2001) 1.30
Kaposi's sarcoma and protection from AIDS dementia complex. AIDS (1998) 1.30
Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med (2007) 1.29
Operative management of displaced femoral head fractures: case-matched comparison of anterior versus posterior approaches for Pipkin I and Pipkin II fractures. J Orthop Trauma (1992) 1.28
Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol (1998) 1.27
HIV prevalence and risk behaviour in needle exchange attenders: a national study. The Collaboration of Australian Needle Exchanges. Med J Aust (1997) 1.26
Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci (2009) 1.25
HIV and AIDS in the Asia-Pacific region: an epidemiological overview. AIDS (1998) 1.24
In vivo production of cytokines and beta (C-C) chemokines in human recurrent herpes simplex lesions--do herpes simplex virus-infected keratinocytes contribute to their production? J Infect Dis (1998) 1.23
Predictors of recent HIV testing in homosexual men in Australia. HIV Med (2002) 1.23
The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend (2005) 1.23
Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat (2010) 1.23
High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat (2007) 1.23
The benefits and risks of mammographic screening for breast cancer. Epidemiol Rev (1992) 1.23
HIV surveillance in hard-to-reach populations. AIDS (2001) 1.22
B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS (2000) 1.20
Self-report is a valid measure of circumcision status in homosexual men. Sex Transm Infect (2008) 1.18
Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer (1987) 1.15
Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol (1998) 1.14
Mast cell activation and migration to lymph nodes during induction of an immune response in mice. J Clin Invest (1998) 1.09